scholarly article | Q13442814 |
P50 | author | Matthew Sperrin | Q50893533 |
Alexander Pate | Q90730969 | ||
Michael Andrew Barrowman | Q92317848 | ||
P2093 | author name string | Rachael Williams | |
Kourtney J Davis | |||
David Webb | |||
Tjeerd Van Staa | |||
Jeanne M Pimenta | |||
P2860 | cites work | Methods for evaluating changes in health care policy: the difference-in-differences approach | Q41711592 |
A Tutorial on Multilevel Survival Analysis: Methods, Models and Applications | Q47094118 | ||
Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. | Q47607188 | ||
Transportability of Trial Results Using Inverse Odds of Sampling Weights. | Q47834798 | ||
Understanding the Hawthorne effect. | Q50794924 | ||
How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? | Q81323651 | ||
Generalized Poisson distribution: the property of mixture of Poisson and comparison with negative binomial distribution | Q82154625 | ||
The Hawthorne effect: stronger than the placebo effect? | Q84530783 | ||
Pragmatic trials: how to adjust for the 'Hawthorne effect'? | Q84818549 | ||
The Hawthorne Effect: a randomised, controlled trial | Q21261930 | ||
Data Resource Profile: Clinical Practice Research Datalink (CPRD) | Q28645951 | ||
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data | Q30955660 | ||
Adaptation and validation of the Charlson Index for Read/OXMIS coded databases | Q33522043 | ||
Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries | Q33823425 | ||
Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial | Q34041659 | ||
Obtaining real-world evidence: the Salford Lung Study. | Q34608276 | ||
What Happened at Hawthorne?: New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies | Q34672356 | ||
The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials | Q35204750 | ||
Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records | Q35951223 | ||
External validity of randomised controlled trials: "to whom do the results of this trial apply?". | Q36003704 | ||
Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
Multidimensional Evidence Generation and FDA Regulatory Decision Making: Defining and Using "Real-World" Data | Q38675569 | ||
Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial | Q38689738 | ||
Streamlining cardiovascular clinical trials to improve efficiency and generalisability | Q38813577 | ||
Real-World Evidence - What Is It and What Can It Tell Us? | Q40427436 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
P304 | page(s) | e000339 | |
P577 | publication date | 2018-10-25 | |
P1433 | published in | BMJ open respiratory research | Q27725957 |
P1476 | title | Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect | |
P478 | volume | 5 |
Search more.